Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 30, 2013

Uhlmann Group Spins Off visiotec GmbH

New company will focus on inspection, monitoring, and control systems for automated pharmaceutical manufacturing processes.

An independent subsidiary of Uhlmann Germany, visiotec GmbH, was created on April 1, 2013 to focus on inspection, monitoring, and control systems for automated pharmaceutical manufacturing processes, the company announced in a press release.

The spin-off addresses the pharmaceutical industry’s demand for a more holistic approach beyond the traditional borders of manufacturing and packaging, said the company. Visiotec will provide solutions for product quality and safety using inline monitoring, based on its expertise in process analytical technologies, such as high-speed, near-infrared analysis and advanced mass-verification technology.

Visiotec GmbH will operate globally from offices in Germany, Switzerland, and the United States. The printing, inspection, and track-and-trace products formerly offered by Uhlmann VisioTec GmbH for packaging applications will be handled by the Uhlmann Group’s dedicated Uhlmann Customer Services division.


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.